EARLY HEARING DETECTION AND INTERVENTION VIRTUAL CONFERENCE
MARCH 2-5, 2021
(Virtually the same conference, without elevators, airplane tickets, or hotel room keys)
10/27/2019 | 8:00 AM - 10:00 AM | Outcomes of Idiopathic Sudden Sensorineural Hearing Loss: Two Decades of Experience | Coconino and La Paz Rooms
Outcomes of Idiopathic Sudden Sensorineural Hearing Loss: Two Decades of Experience
Objectives: 1) Determine demographic and medical risk factors of patients who presented with idiopathic sudden sensorineural hearing loss (ISSNHL); 2) identify the modality of treatments they underwent; and 3) evaluate long-term follow up and hearing outcomes.
Design: This is a retrospective review of patients who presented to a tertiary care medical center with unilateral ISSNHL between January 1998 and December 2017. Demographics, medical co-morbidities, pure tone audiometry, and treatment outcomes were collected.
Results: Two hundred and four patients met inclusion criteria (mean age: 55.4 years, 52.5% female, 83.3% Caucasian). Of these, 129 (63.2%) did not receive treatment prior to our evaluation and were included in the analysis. Pre-treatment pure tone average (PTA) was 61.9 ± 2.5 decibels (dB). Mean speech recognition threshold (SRT) was 44.6 ± 2.4 dB and mean word recognition score (WRS) was 64.5 ± 3.8 %. Seventy-six patients (59.9%) were treated with oral corticosteroids. The remainder were treated with intratympanic (IT) steroid injections (7.2%) or oral steroids followed by IT injections (19.4%). Post-treatment PTA (45.6 ± 2.6 dB) was improved from baseline (p<0.01), as was SRT (27.5 ± 1.9 dB; p<0.01) and WRS (81.8.0 ± 3.1%, p<0.01). Mean follow-up duration was 17.9 ( 29.2) months. Patients were recommended to use hearing aids (26.3%), contralateral routing of signal device (13.6%), bone-anchored hearing aids (4.5%), or cochlear implant (1.9%). Less than 20% of patients reported active use of hearing amplification. Ninety patients (69.8%) experienced subjective improvement in hearing while only 55 (42.6%) showed audiometric improvement.
Conclusion: Patients with ISSNHL experienced audiometric improvement after treatment but many had persistent hearing loss. The duration of follow-up was short with most patients lost to follow up after two years. Future studies are needed to identify factors that contribute to short follow-up and poor compliance with hearing amplification.
- Determine demographic and medical risk factors of patients who presented with idiopathic sudden sensorineural hearing loss (ISSNHL)
- Identify the modality of treatments patients with ISSNHL underwent
- Evaluate long-term follow up and hearing outcomes for ISSNHL
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Yanjun Xie
(), University of Michigan , xieya@med.umich.edu;
Dr. Jun is a second year resident in otolaryngology head and neck surgery at the University of Michigan.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Norman Orabi
(), University of Michigan School of Medicine, orabi@med.umich.edu;
Mr. Orabi is a medical student at the University of Michigan.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Teresa Zwolan
(), University of Michigan Otolaryngology, zwolan@med.umich.edu;
Dr. Zwolan is the head of the cochlear implant program at the University of Michigan.
ASHA DISCLOSURE:
Financial -
Nonfinancial -
Gregory Basura
(), University of Michigan; Department of Otolaryngology, gbasura@umich.edu;
Dr. Basura is an Assistant Professor at the department of Otolaryngology/Head and Neck
Surgery at the University of Michigan; Division of Otology/Neurotology-Skull Base
Surgery. He has training in both basic neuroscience and surgery. He is involved in
investigating disease processes like tinnitus and auditory aberrancy from a fundamental
basic science perspective as well as maintaining the clinical opportunity to extrapolate
investigative inquiry to the human condition. He is involved in an outreach
and long-term medical partnership with Komfo Anokye Teaching Hospital (KATH) in
Kumasi, Ghana that is geared towards establishing sustained platforms to expand
education and research initiatives in otology and audiology.
ASHA DISCLOSURE:
Financial -
Nonfinancial -